- News
News
Welcome to the homepage of AIHTA!
AIHTA is an academic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 168 (March 2024)
Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas
Fact Sheet No. 169 (March 2024)
Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours
Fact Sheet No. 170 (March 2024)
Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: „Unmet Need“ (ungedeckte Bedarfe): Eine Definition steht noch aus
- Wundversorgung: Integrierte digitale Wundpflegesysteme
- Implantierte Sensoren: Messung und Monitoring des pulmonal-arteriellen Drucks bei Herzinsuffizienz
- Finanzielle Anreize in der integrierten Versorgung
- Künstliche Intelligenz: Erkennung und Charakterisierung von Darmkrebsvorstufen bei der Darmspiegelung
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 164 (February 2024)
Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 165 (February 2024)
Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma
Fact Sheet No. 166 (February 2024)
Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 167 (February 2024)
Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC)
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Zugang zu Medikamenten in Österreich: Warum Geschwindigkeit nicht alles ist
- Autologe Fetttransplantation bei Arthrose
- Telepathologie bei der intraoperativen Schnellschnittuntersuchung
- Liposuktion zur Entfernung subkutaner (großer) Lipome
- Calcitonin-Gene-Related-Peptide (CGRP)-Antagonisten zur Migräneprävention
- Termine
- Themen-Vorschau
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Advanced Practice Nursing (APN): Kompetenz, Leadership, Karriere
- Unterstützung rationaler Impfpolitik
- Implementierung der „Krankenhausausnahmegenehmigung“ für ATMPs in sechs ausgewählten EU-Ländern
- Telemedizin und Künstliche Intelligenz im intramuralen Bereich Österreichs
- Cranberries (Vaccinium macrocarpon) zur Prävention von Harnwegsinfekten
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you two new Fact Sheets.
Fact Sheet No. 162 (Jänner 2024)
Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies
Fact Sheet No. 163 (Jänner 2024)
Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer
Announcement
Role of Public Contributions to the Development of Health Innovations
New (pharmaceutical) products are getting increasingly more expensive. As a result of this trend accessibility of pharmaceuticals decreases. However, not all innovation can be attributed to private companies. Subsequently, the role of public institutions like universities, university spin-offs, and publicly funded biotech start-ups is largely being disregarded at the price negotiations. Public funding in the form of research grants, tax incentives, utilisation of clinical infrastructure or regulatory measures make a major contribution.
Article 57 of the proposed Pharmaceutical Legislation (PL, Directive) will require market authorization applicants to publicly declare any direct financial support for R&D received from public authorities. The aim of our research (funded by EU Horizon Europe Grant Agreement Number 101095593) is to increase transparency in (pharmaceutical) R&D to mitigate the risk of market failure associated with information asymmetry by analyzing pharmaceutical R&D expenditures of bringing a new medicine to the market and which factors influence these expenditures and to identify the categories needed to capture direct or indirect public contributions to R&D, to provide a framework for standardized reporting of public contributions and to reduce ambiguity in the interpretation of “direct” and “indirect” public contributions.
The report is the first output of the project HI-PRIX (WP2, sub-deliverable 2.2).
Publication: HTA Project Report No. 158: https://eprints.aihta.at/1499/
Contact: Claudia Wild
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Klimaschutz - wer schnell agiert, hilft doppelt
- Leitlinien und derzeitiges Disease-Management-Programm für Depression im Vergleich
- Nusinersen, Onasemnogen-Abeparvovec, Risdiplam und Kombinationstherapien bei SMA-Patient*innen
- Progressionshemmende Brillengläser für Kinder und Jugendliche mit fortschreitender Myopie
- HTA-Methoden zur Unterstützung der Gesundheitsgerechtigkeit
- Termine
- Themen-Vorschau
Article
Job advertisement: Head of Finance/Human Resources
The HTA Austria, Austrian Instittute for Health Technology Assessment GmbH (AIHTA) seeks an 'Bereichsleitung Finanzen, Controlling & Personalwesen', part-time - for 30 hours per week
Applications are to be submitted by September 5th 2025 under the subject "Job advertisement: Head of Finance/Human Resources" at office@aihta.at.
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you five new Fact Sheets.
Fact Sheet No. 157 (November 2023)
Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM)
Fact Sheet No. 158 (November 2023)
Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC)
Fact Sheet No. 159 (November 2023)
Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC)
Fact Sheet No. 160 (November 2023)
Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis
Fact Sheet No. 161 (November 2023)
Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
